Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HFA-152a · 2 trials · 1 indication
\[AUC(0-4h)\] was assessed for Mucociliary clearance (MCC) in participants following administration of nebulized 99mTc on Day 7. Gamma scintigraphy was utilized to conduct assessments.
| Arm | Type | Description |
|---|---|---|
| Participants receiving HFA-152a followed by HFA-134a | EXPERIMENTAL | Participants will receive HFA-152a MDI in treatment period 1 followed by HFA-134a MDI in treatment period 2. There will be a washout period between the treatment periods. |
| Participants receiving HFA-134a followed by HFA-152a | EXPERIMENTAL | Participants will receive HFA-134a MDI in treatment period 1 followed by HFA-152a MDI in treatment period 2. There will be a washout period between the treatment periods. |
| HFA-152a followed by HFA-134a | EXPERIMENTAL | - |
| HFA-134a followed by HFA-152a | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| HFA-152a | DRUG | HFA-152a will be administered. |
| HFA-134a | DRUG | HFA-134a will be administered. |
| Radiolabeled saline solution | OTHER | Radiolabeled saline solution is administered via oral inhalation |
Inclusion Criteria: * Participant must be aged greater than equal to (\>=)18 years at the time of signing the informed consent. * Participants with asthma for \>= 6 months, defined as: * Documented history of asthma, as defined by Global Initiative for Asthma (GINA) * Receiving one of following ...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 27 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | tilrekimig and rHuPH20, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
HFA-152a is an investigational propellant being developed by GSK plc for use in inhaled respiratory medicines, with asthma as the studied indication. It is a hydrofluoroalkane, 1,1-difluoroethane, evaluated as an alternative to the propellant HFA-134a in metered dose inhalers. It is not a stand-alone asthma therapy but a component of the inhaler delivery system.
HFA-152a is being studied as the propellant that delivers asthma medication from a pressurized metered dose inhaler, replacing HFA-134a. GSK is testing whether exposure to HFA-152a is safe in people with asthma and whether it affects mucociliary clearance, the lung's mechanism for clearing inhaled particles. It is not itself a bronchodilator or anti-inflammatory treatment.
GSK plc, which trades under the ticker GSK, is the developer of HFA-152a. The company is running the clinical program evaluating the propellant in asthma and in healthy participants, including studies conducted in the United States, Argentina, Canada and the United Kingdom.
HFA-152a is in Phase 3 development. A Phase 3 study comparing four weeks of exposure to HFA-152a and HFA-134a in participants with asthma is currently recruiting. An earlier Phase 1 study of the effect of both propellants on mucociliary clearance in healthy participants has been completed. HFA-152a is investigational and has not been approved.
Two trials are listed for HFA-152a. NCT07645248 is a recruiting Phase 3 study comparing the safety of four weeks of exposure to HFA-152a and HFA-134a in 110 participants with asthma across the United States, Argentina, Canada and the United Kingdom. NCT06506266 was a completed Phase 1 study of mucociliary clearance in 24 healthy participants in the United Kingdom.
No. HFA-152a is 1,1-difluoroethane, while HFA-134a is 1,1,1,2-tetrafluoroethane. They are distinct hydrofluoroalkane propellants. GSK's trials compare the two directly, using HFA-134a as the comparator to assess the safety and lung-clearing effects of HFA-152a in asthma and in healthy participants.